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Background
Resistance outcome for treated children in low resource
countries is scarce. We aimed to describe the frequency
and the profile of resistant virus in children treated with at
least 12 months of WHO advised highly active antiretro-
viral therapy (HAART) in a large access program in
Mozambique.
Methods
Between December 2003 and December 2006, 515 chil-
dren (median age: 36.8 months) were included, 97%
received a combination of d4T plus 3TC and nevirapine.
HIV-1 RNA was transversally performed once using the
Roche Amplicor v1.5 test. HIV-1 genotypic resistance tests
were performed on available plasma samples when HIV-1
RNA was > 3 log10 copies/ml. Drug resistance was inter-
preted according to the 2007 French ANRS resistance algo-
rithm.
Results
Viral load was available for 498 out of the 515 children.
Among them, 134 (27%) had a viral load > 3 log10 cop-
ies/ml and genotypic resistance test could be performed
for 87 children. The overall frequency of viruses showing
genotypic resistance to at least 1 antiretroviral drug was
90%. The prevalence of children infected with virus with
≥ 1 major mutation conferring drug resistance to NRTIs
and NNRTIs were 85% and 90%, respectively. M184V
conferring resistance to lamivudine was the most com-
mon NRTI mutation. Thymidine analogs mutations
(TAMs) conferring resistance to ZDV or d4T were
observed in 15%. Resistance to Tenofovir, Abacavir and
ddI were described in 6%, 5% and 3.5% respectively. The
NRTIs Multi Drug Resistance complex (Q151M) was
found in 3 cases. Unexpectidely, five children (6%) had
developed extensive resistance to NNRTIs inducing resi-
tance to the new NNRTI etravirine (TMC 125). The only
factor identified by multivariate analysis as being associ-
ated with this broad spectrum resistance was the duration
of treatment: aOR: 10.15 [95% CI 1.59–64.94], p < 0.05
for treatment for longer than 24 months. The level of viral
replication at the time of genotyping was not predictive.
Conclusion
After experiencing failure with HAART containing two
drugs with low genetic barrier, almost all children have at
least lamivudine and NNRTI resistance. Broad spectrum
resistances to second NRTIs line (ddI, ABC, TDF) con-
cerned 6% of children. Multi drug resistance to all NRTIs
was found in 3.5%. Resistance to etravirine was descibed
in five children (6%).
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